araag2/HINT huggingface dataset:
Clinical trial NCT01378676 (phase 2, status: completed)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: placebo (part a), ck-2017357 (part a), ck-2017357 (part a), ck-2017357 (part a), riluzole 50 mg (part b), placebo (part b), ck-2017357 (part b), ck-2017357 (part b), ck-2017357 (part b)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC(CC)N1C(=O)NC2=NC=C(N=C12)C#C, CCC(CC)N1C(=O)NC2=NC=C(N=C12)C#C, CCC(CC)N1C(=O)NC2=NC=C(N=C12)C#C, NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC(CC)N1C(=O)NC2=NC=C(N=C12)C#C, CCC(CC)N1C(=O)NC2=NC=C(N=C12)C#C, CCC(CC)N1C(=O)NC2=NC=C(N=C12)C#C
Eligibility criteria:

        Key Inclusion Criteria:

          1. Able to comprehend and willing to sign an Informed Consent Form (ICF)

          2. Males or females 18 years of age or older

          3. A diagnosis of familial or sporadic ALS (defined as meeting the possible,
             laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS
             according to the World Federation of Neurology El Escorial criteria)

          4. Maximum voluntary grip strength in at least one hand between 10 & 40 pounds (females)
             and 10 & 60 pounds (males)

          5. Upright Slow Vital Capacity (SVC) >50% of predicted for age, height, and sex

          6. Able to swallow tablets with water

          7. Willing and able to remain off riluzole for 4 weeks (Part A only)

          8. Currently taking and tolerating a stable dose of 50 mg BID riluzole (Part B only)

          9. Willing and able to reduce daily dose of riluzole to 50 mg for 4 weeks (Part B only)

         10. Willing and able to refrain from caffeine-containing products during study
             participation

         11. Willing and able to remain off warfarin and theophylline-containing medications during
             study participation

         12. Has a caregiver who is capable of observing and reporting patient status, and also
             assisting in the proper use of nocturnal oximetry equipment

         13. Able to perform pulmonary function tests

        Key Exclusion Criteria:

          1. Life expectancy <3 months

          2. Participation in any trial in which receipt of investigational study drug occurred
             within 30 days or 5 half-lives of the prior agent, whichever is greater, prior to
             dosing

          3. Any prior treatment with CK-2017357

          4. Use of non-invasive positive pressure ventilation (NIPPV) for any part of the day or
             night

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00530621 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: enzastaurin, placebo, pemetrexed
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Laboratory confirmed diagnosis of NSCLC with locally advanced or metastatic disease
             which cannot be cured.

          -  Participants must have disease which progressed after 1 prior systemic cytotoxic
             chemotherapy regimen for advanced disease.

          -  At least 1 measurable lesion.

          -  Must have stopped all previous systemic therapies for cancer for at least 2 weeks
             prior to enrollment.

          -  Must be able to follow study guidelines and be able to show up for appointments.

        Exclusion Criteria:

          -  Treatment within the last 30 days with a drug that has not received regulatory
             approval for any indication at the time of study entry.

          -  Previous treatment with enzastaurin or pemetrexed.

          -  Concurrent administration of any other antitumor therapy.

          -  Inability to swallow tablets.

          -  Pregnant or breastfeeding.
Clinical trial NCT00642278 (phase 2, status: completed)
Conditions: diabetes mellitus, type ii, diabetes mellitus, non insulin dependent
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, F60.7, R39.192, E24.0, D81.818, D81.819, Z63.6, G40.42
Drugs: canagliflozin (jnj-28431754), sitagliptin, placebo
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have a diagnosis of type 2 diabetes mellitus

          -  Hemoglobin A1c levels >=7% and <=10.5%

          -  taking a stable daily dose of metformin

          -  Body mass index (BMI) 25 to 45 kg/m2 except those of Asian descent who must have a BMI
             of 24 to 45 kg/m2

          -  Stable body weight

          -  Serum creatinine <=1.5 mg/dL (132.6 umol/L) for men and <=1.4 mg/dL (123.76 umol/L)
             for women

        Exclusion Criteria:

          -  Patients must not have prior exposure or known contraindication or suspected
             hypersensitivity to canagliflozin (JNJ-28431754)

          -  Known contraindication or suspected hypersensitivity to sitagliptin or metformin

          -  A history of diabetic ketoacidosis or type 1 diabetes mellitus

          -  History of pancreas or beta-cell transplantation

          -  History of active proliferative diabetic retinopathy

          -  History of hereditary glucose-galactose malabsorption or primary renal glucosuria
Clinical trial NCT00584974 (phase 2, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: sep-225289, sep-225289, venlafaxine, placebo
SMILES: N[C@@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C12, N[C@@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C12, [O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  The duration of the current episode must be at least 1 month but not longer than 12
             months.

          -  Subjects must have a primary diagnosis of Major Depressive Disorder.

          -  Subjects must have had at least one previous, diagnosed episode of MDD in the past 5
             years.

          -  MDD must be the condition that was chiefly responsible for motivating the subject to
             seek treatment.

          -  Subject is in general good health.

        Exclusion Criteria:

          -  Subject is participating in, has participated in, or plans to participate in any
             investigational drug study.

          -  Subject who has donated blood within the last 30 days or plans to donate blood during
             and 30 days following participation.

          -  Known failure to respond (in the past 5 years) to two adequate (dose and duration)
             antidepressant medications with distance mechanisms of action including tricyclics.

          -  Subjects who have undergone Electroconvulsive Therapy treatment.

          -  Treatment with fluoxetine, in the 6 weeks before baseline.

          -  Subject with psychotic disorders, anorexia nervosa, bulimia or post-traumatic stress
             disorder.

          -  Subject with a history or presence of bipolar disorder (i.e., current or past history
             of manic episode).

          -  Subjects with Obsessive Compulsive Disorder.

          -  Subjects with a lifetime diagnosis of Panic Disorder.

          -  Subject received treatment with antidepressants within 2 weeks.

          -  Subject with lifetime history of suicidal attempts, alcohol dependence or abuse,
             drug(s) dependence or abuse (excluding nicotine and caffeine) or has a positive urine
             drug screen.

          -  Subject has a history of significant risk of suicide or homicide.

          -  Bereavement - Defined as death of a loved one within 3 months.

          -  Subject has a documented history of HIV, hepatitis B or hepatitis C.
Clinical trial NCT00667004 (phase 2, status: completed)
Conditions: dry eye disease
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: ecabet ophthalmic solution, placebo
SMILES: [H][C@@]12CCC3=CC(C(C)C)=C(C=C3[C@@]1(C)CCC[C@@]2(C)C(O)=O)S(O)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with dry eye disease

        Exclusion Criteria:

          -  Dry eye disease secondary to surgery
Clinical trial NCT00299871 (phase 2, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: lixisenatide (ave0010)
SMILES: [V].[H][C@](C)(O)[C@]([H])(N=C(O)CN=C(O)[C@]([H])(CCC(O)=O)N=C(O)CN=C(O)[C@@]([H])(N)CC1=CN=CN1)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCC(O)=N)C(O)=N[C@@]([H])(CCSC)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(C)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC1=CNC2=CC=CC=C12)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CC(O)=N)C(O)=NCC(O)=NCC(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CO)C(O)=NCC(O)=N[C@@]([H])(C)C(=O)N1CCC[C@@]1([H])C(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N)[C@@]([H])(C)CC)[C@@]([H])(C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Males, females, age 30, - 75 years, type 2 diabetes mellitus, treated with metformin
             ≥1.0 g/day, at a stable dose for at least 3 months, BMI 25 - 40 kg/m2, HbA1C ≥7.0% and
             <9.0%.

        Exclusion Criteria:

          -  Type 1 diabetes, pregnancy, lactation, women of childbearing potential, treatment with
             other antidiabetic agents than metformin, history of metabolic acidosis,
             hemoglobinopathy or hemolytic anemia, clinically significant medical abnormalities.
Clinical trial NCT00615056 (phase 2, status: completed)
Conditions: colorectal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab (avastin), folfiri (irinotecan, leucovorin, 5-fluorouracil [5fu]), ag-013736 (axitinib), folfox (oxaliplatin, leucovorin, 5-fluorouracil [5fu]), ag-013736 (axitinib), folfiri (irinotecan, leucovorin, 5-fluorouracil [5fu]), bevacizumab (avastin), folfox (oxaliplatin, leucovorin, 5-fluorouracil [5fu])
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, FC1=CNC(=O)NC1=O, CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically documented colorectal cancer plus one of the following:

          -  Failure of one prior irinotecan- or oxaliplatin-containing regimen, or

          -  Adjuvant refractory to irinotecan- or oxaliplatin-containing regimen.

        Exclusion Criteria:

          -  Prior treatment in first line metastatic setting with more than one regimen

          -  Prior irradiation of more than 25% of bone marrow.
Clinical trial NCT01370863 (phase 2, status: terminated)
Conditions: gastroesophageal reflux disease
ICD codes: K21.9, K21.00, K21.01
Drugs: spd557, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    this study was terminated early due to recruitment difficulties. there were no safety concerns.
  
Eligibility criteria:

        Inclusion criteria:

          1. Written ICF signed voluntarily before the first trial related activity.

          2. Subjects with a history of GERD symptoms (i.e., heartburn and/or regurgitation) during
             the last 6 months

          3. Subjects on a stable dose of PPIs, compliant for at least 6 weeks prior to screening.

          4. ≥3 days per week with heartburn and/or regurgitation symptoms of at least moderate
             severity and a minimum of 25 liquid containing reflux events over 24h (pH/MII
             monitoring).

        Exclusion criteria:

          1. Subjects with prior endoscopic anti-reflux procedure or major GI surgery or subjects
             with major GI disorders.

          2. Presence of severe and clinically uncontrolled cardiovascular, liver or lung disease,
             neurologic, cancer or AIDS.

          3. Alarm symptoms suggestive of malignancies or organic disease.
Clinical trial NCT00261703 (phase 2/phase 3, status: completed)
Conditions: head and neck neoplasms
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: docetaxel, cisplatin, 5-fluorouracil (5-fu), radiotherapy, cisplatin, 5-fluorouracil (5-fu), radiotherapy
SMILES: FC1=CNC(=O)NC1=O, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Head and Neck cancer locally advanced (oral cavity, oropharynx, hypopharynx or larynx)
             but without evident metastasis.

          -  Inoperable tumor after revision by a multidisciplinary oncology team.

          -  Proved epidermoid carcinoma.

          -  ECOG = 0-1

          -  Good hematologic function (i.e, hemoglobin > 10 g/dl, ...)

          -  Good hepatologic function

          -  Good renal function

        Exclusion Criteria:

          -  Pregnant or breast-feeding women. Potential child-bearing women should use an
             effective conceptive method and should have a negative pregnancy test at least the
             week before entering the study.

          -  Nasopharynx, nasal cavity and paranasal sinusitis will be excluded

          -  Previous chemotherapeutic or radiotherapeutic treatment for this disease.

          -  Previous or current neoplasms in other locations, except in situ cervicouterine cancer
             properly treated or basal cell or squamous cell carcinoma

          -  Symptomatic peripheral neuropathy

          -  Other clinical severe diseases

          -  Concomitant treatment with corticoids within 6 months prior to inclusion.

          -  Concomitant treatment with any other neoplastic therapy

          -  Previous treatment for current disease.

          -  Loss of weight greater than 10% within the last 3 months.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00448240 (phase 2/phase 3, status: terminated)
Conditions: head and neck cancer, carcinoma, squamous cell
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11, C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, C44.42
Drugs: erlotinib
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    low accrual, funding
  
Eligibility criteria:

        Inclusion Criteria:

          -  Squamous cell carcinoma of the head and neck region that is metastatic, recurrent or
             persistent after surgery and/or radiation

          -  No prior chemotherapy for metastatic, recurrent or persistent disease

        Exclusion Criteria:

          -  Not more than 1 prior adjuvant or neoadjuvant chemotherapy regimen is allowed

          -  Chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who
             have not recovered from adverse events due to agents administered more than 4 weeks
             earlier
Clinical trial NCT00168064 (phase 2, status: completed)
Conditions: mycosis fungoides
ICD codes: C84.07, C84.00, C84.02, C84.06, C84.03, C84.08, C84.09
Drugs: mechlorethamine-mch (nitrogen mustard)
SMILES: CN(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with mycosis fungoides confirmed by a skin biopsy

          -  Stage I or IIA patients must have been treated previously with prior topical therapies
             including PUVA, UVB, topical steroids, but not NM within the past 2 years, or topical
             carmustine (BCNU)

          -  Patients must be otherwise healthy with acceptable organ function.

          -  Prior to initiating study therapy, patients must not have had topical therapy within
             four weeks

          -  Lab values within normal range

          -  Willing/able to give consent

          -  Must use effective means of contraception if of childbearing potential

        Exclusion Criteria:

          -  Newly diagnosed mycosis fungoides with no prior therapy

          -  A prior history of treatment with topical NM within the past 2 years or topical
             carmustine (BCNU)

          -  Use of topical or systemic therapies for MF within four (4) weeks of entry in the
             study

          -  Patients with a diagnosis of stage IIB-IV MF

          -  Serious known concurrent medical illness or infection, which could potentially present
             a safety risk and/or prevent compliance with the requirements of the treatment program

          -  Pregnant or nursing females, or males and females of childbearing potential, not using
             an effective means of contraception

          -  Patients who have had radiation therapy within one year of study start

          -  Patients who have a history of a higher T score than T2 or a higher N score than N1

          -  Patients who do not agree to do all labs at one site
Clinical trial NCT00422656 (phase 2, status: completed)
Conditions: waldenstrom's macroglobulinemia
ICD codes: C88.0
Drugs: perifosine
SMILES: CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Must have received prior therapy for their WM and have relapsed or refractory WM. Any
             number of prior therapies is acceptable

          -  Measurable disease, defined as presence of immunoglobulin M paraprotein with a minimum
             IgM level of equal to or greater than 2 times the ULN and over 10% of
             lymphoplasmacytic cells in bone marrow

          -  ECOG Performance Status 0,1, or 2

          -  Laboratory values as described in the protocol

          -  Life expectancy of greater than 12 weeks

        Exclusion Criteria:

          -  Uncontrolled infection

          -  Other active malignancies

          -  CNS involvement

          -  Cytotoxic chemotherapy less than 3 weeks, or biologic therapy less than 2 weeks, or
             corticosteroids less than 2 weeks prior to registration.

          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
             considered investigational

          -  Pregnant or nursing women

          -  Known to be HIV positive

          -  Radiation therapy less than 2 weeks prior to registration
Clinical trial NCT00597116 (phase 2, status: terminated)
Conditions: mesothelioma
ICD codes: C45.9, C45.0, C45.1, C45.2, C45.7
Drugs: vinorelbine, vandetanib
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
Reason stopped: 
    recruitment stopped according to early stopping rule (by protocol)
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with mesothelioma

          -  Previously treated with only one course of chemotherapy for mesothelioma

          -  No previous treatment with vinorelbine

          -  No serious heart problems within the last 3 months

        Exclusion Criteria:

          -  Serious abnormal laboratory values

          -  Severe or uncontrolled disease or condition as judged by the Investigator

          -  Pregnant or breast-feeding women

          -  Other cancers within the last 5 years

          -  Major surgery or radiation therapy within 4 weeks prior to starting study therapy

          -  Receipt of any investigational agents within 30 days prior to commencing study
             treatment.
Clinical trial NCT01448902 (phase 2, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: oc000459, placebo
SMILES: CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males aged 18 to 50 years with a history of symptoms of grass pollen related allergic
             rhinitis within the previous two years.

          -  Subjects must be free from significant cardiac, pulmonary, gastrointestinal, hepatic,
             renal, haematological, neurological and psychiatric disease as determined by history,
             physical examination and screening investigations.

          -  FEV1 within normal limits (≥90% of predicted).

          -  Atopy defined by a positive cutaneous response to mixed grass pollen within the last
             12 months or at screening.

          -  Asymptomatic at screening

          -  Non smokers for at least the past 12 months

        Exclusion Criteria:

          -  Medical conditions likely to affect the outcome of the study.

          -  Nasal conditions likely to affect the outcome of the study, i.e. nasal septal
             perforations, nasal polyps, sinus disease, chronic nasal obstruction, or other nasal
             diseases.

          -  Presence of any respiratory disease other than a history of mild stable asthma not
             requiring treatment and associated with normal lung function

          -  Immunotherapy treatment course including inhaled or local corticosteroids in the past
             28 days.